Find your next paid study

Vanderbilt-Ingram Cancer CenterNCT07673367

Prostate CancerProstate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Disease+16 more

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)

The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivat…

Prostate CarcinomaRecurrent Prostate Carcinoma

A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT)

This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide,…

City of Hope Medical CenterNCT07202247

Metastatic Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8+2 more

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive s…

NRG OncologyNCT05408845

Advanced Ovarian CarcinomaRecurrent Ovarian CarcinomaStage II Ovarian Cancer AJCC v8+2 more

A Randomized, Double-Blind, Placebo Controlled, Study to Investigate Efficacy of a Probiotic Intervention on the Gut and Vaginal Microbiome of Ovarian Cancer Patients Undergoing Treatment With Platinum Chemotherapy

This clinical trial evaluates the effects a probiotic intervention has on the gut and vaginal microbiome in patients undergoing chemotherapy for ovarian cancer…

Ohio State University Comprehensive Cancer CenterNCT07144826

Observational

Planning Advance Care Together (PACT) to Improve Engagement in Advance Care Planning

This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for…

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Hematologic Malignancy+1 more

Fred Hutchinson Cancer CenterNCT04515810

AstrocytomaGliomaRecurrent Glioblastoma

A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Mo…

National Cancer Institute (NCI)NCT06344130

~$10 – $5,625

Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ov…

Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)

This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is g…

Recurrent Meningioma

Joshua PalmerNCT07150806

Recurrent Multiple MyelomaRefractory Multiple Myeloma

Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma

This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating p…

National Cancer Institute (NCI)NCT07463807

~$10 – $5,625

Recurrent Multiple MyelomaRefractory Multiple Myeloma

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexam…

Roswell Park Cancer InstituteNCT06622005

EGFR Gene MutationGlioblastomaMGMT-Unmethylated Glioblastoma+1 more

Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma

This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treati…